Rallybio Corporation — Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2022; filed March 6, 2023. Rallybio is a clinical-stage biotechnology company developing therapies for severe and rare diseases. It has no approved products and has never generated revenue from product commercialization.
Financial Performance and Position
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No commercial revenue |
| Research and development expense | $40.7 million | $26.9 million | +$13.8 million |
| General and administrative expense | $27.2 million | $18.7 million | +$8.5 million |
| Total operating expenses | $67.9 million | $45.6 million | +$22.2 million |
| Operating loss | $(67.9) million | $(45.6) million | Loss increased |
| Net loss | $(66.7) million | $(47.0) million | Loss increased $19.6 million |
| Net loss per share | $(2.09) | $(1.84) | More loss per share |
| Net cash used in operating activities | $(57.3) million | $(45.5) million | Use increased $11.8 million |
| Net cash used in investing activities | $(112.2) million | $(2.3) million | Primarily marketable-security purchases |
| Net cash provided by financing activities | $51.1 million | $83.0 million | Lower financing inflow |
- Gross cash, cash equivalents and marketable securities totaled $169.0 million at December 31, 2022, consisting of $57.0 million of cash and cash equivalents and $112.0 million of marketable securities.
- Total assets were $180.4 million and stockholders’ equity was $169.3 million. Total liabilities were $11.1 million.
- The filing reports no credit facility, material debt financing, or ongoing material financing commitments. Operating lease liabilities totaled $0.6 million.
- Accumulated deficit was $160.7 million at year-end. Because the company has no revenue, gross and operating margins are not meaningful; operating expenses effectively represent the operating loss.
- Stock-based compensation increased to $9.5 million from $3.6 million in 2021, including $3.5 million classified in general and administrative expense and $3.5 million in research and development expense.
Material Changes Versus 2021
- Research and development spending increased 51%, primarily due to clinical development of RLYB212 and RLYB116, RLYB331 preclinical work, higher personnel costs, and a $3.1 million in-process research and development charge related to the RLYB331 license acquisition.
- General and administrative spending increased 45%, reflecting higher headcount, $3.5 million of additional non-cash stock compensation, and a full year of public-company costs.
- Interest income increased to $2.0 million from $0.1 million as cash was invested in marketable securities.
- Cash used in investing activities increased substantially because the company purchased $201.3 million of marketable securities and received $89.5 million from maturities.
- In November 2022, Rallybio raised approximately $54.8 million gross, or $50.8 million net, through common stock and pre-funded warrant issuance. The offering included 5,803,655 common shares and warrants exercisable for up to 3,333,388 additional shares.
- RLYB331 was added through a worldwide exclusive license from Sanofi/Kymab. Rallybio paid $3.0 million upfront and could owe up to $43.0 million in development and regulatory milestones, up to $150.0 million in commercial milestones for the first indication, additional amounts for later indications, and sales royalties.
- The company entered a multi-year, multi-target collaboration with AbCellera to co-develop up to five rare-disease targets. Costs were not material in 2022.
Pipeline, Outlook and Management Commentary
- RLYB212: Lead subcutaneous anti-HPA-1a antibody for prevention of FNAIT. The Phase 1b proof-of-concept study produced preliminary 2022 results showing more than a 90% reduction in mean platelet elimination half-life versus placebo. The filing reports that proof-of-concept was announced in the first quarter of 2023, with additional Phase 1 repeat-dose data expected in the fourth quarter of 2023.
- RLYB116: Subcutaneous C5 inhibitor for potential treatment of PNH, generalized myasthenia gravis and other complement-mediated diseases. In a Phase 1 single-dose study, all six subjects receiving 100 mg showed greater than 99% reduction in free C5 within 24 hours; terminal half-life exceeded 300 hours. Initial multiple-ascending-dose data were expected in the fourth quarter of 2023.
- RLYB114: Pegylated C5 inhibitor in preclinical development for ophthalmic disorders, with a goal of partnering the program with an ophthalmology-focused company.
- RLYB331: Preclinical MTP-2 antibody for severe anemia and iron overload, including beta thalassemia and certain myelodysplastic syndromes. IND-enabling work is ongoing.
- Exscientia collaboration: The joint venture is pursuing an oral ENPP1 inhibitor for hypophosphatasia. In vivo efficacy data were expected in the second half of 2023, followed by potential IND-enabling studies.
- Rallybio discontinued further development of RLYB211 in favor of RLYB212, citing RLYB212’s development profile, data generated to date, and manufacturing and supply efficiencies.
- Management stated that $169.0 million of cash, cash equivalents and marketable securities at year-end was expected to fund operating expenses and capital requirements into the first quarter of 2025. The filing also states that additional capital will be required to complete development and commercialization of its candidates.
- The company expects continued operating losses and negative cash flows. It has no current product revenue and no committed external source of capital.
Key Risks and Contingencies
- RLYB212 and RLYB116 remain in early-stage clinical development, and favorable preliminary results may not predict later safety, efficacy or regulatory outcomes.
- Clinical trials may face enrollment challenges because the target diseases are rare; delays, protocol changes, safety findings or regulatory requests could materially increase costs and extend timelines.
- RLYB212 may require a companion diagnostic or other screening infrastructure. Failure to develop, validate and obtain regulatory clearance for required tests could delay approval or limit commercial adoption.
- The company relies on contract research organizations, clinical sites, contract manufacturers and collaborators, without owning manufacturing facilities or having commercial manufacturing commitments.
- Rallybio will need substantial additional financing. Future equity financing could dilute investors, while debt or partnership financing could impose restrictive terms or require relinquishing rights.
- Competition is significant, particularly for RLYB116 in PNH and generalized myasthenia gravis, where approved and late-stage therapies already exist.
- License agreements include potentially significant milestone and royalty obligations, and failure to meet diligence or other contractual obligations could jeopardize rights to key assets.
- Intellectual-property protection, regulatory approval, reimbursement, pricing, supply-chain continuity, cybersecurity, clinical-trial liability and evolving healthcare laws remain material uncertainties.
- The company reports no material pending litigation and no off-balance-sheet arrangements as of December 31, 2022.
Investor Verification Checklist
- Verify the company’s cash runway assumptions and the timing and size of future financing needs.
- Review the complete RLYB212 Phase 1b dataset and subsequent repeat-dose safety and pharmacokinetic results.
- Assess whether RLYB212’s proposed screening or companion-diagnostic strategy will be accepted by regulators and payors.
- Monitor RLYB116 multiple-dose data, selection of target indications and competitive developments in PNH and generalized myasthenia gravis.
- Reconcile reported cash, cash equivalents and marketable securities with operating cash burn and investment maturities.
- Track potential dilution from 3,333,388 pre-funded warrants, equity compensation awards and the company’s $100 million at-the-market facility.
- Review milestone, royalty and collaboration obligations associated with Sanofi/Kymab, Sobi, Prophylix, Affibody, Exscientia and AbCellera.
- Confirm the status of RLYB211 discontinuation, RLYB331 IND-enabling work and the Exscientia program’s in vivo efficacy milestones.